[A case of advanced gastric cancer with pyloric stenosis and obstructive jaundice responding to s-1/paclitaxel combination therapy after endoscopic balloon dilatation and endoscopic biliary drainage].

A 65-year-old female who complained of appetite loss and upper abdominal pain was diagnosed as unresectable advanced gastric cancer with pyloric stenosis and obstructive jaundice by peritoneal and lymph node metastases. After endoscopic balloon dilatation and endoscopic biliary drainage, S-1(80 mg/m(2)/day, days 1-14 with 1 week rest)/pacli- taxel(PTX)(50 mg/m(2)/day, day 1, day 8)combination therapy was done. After one course of the chemotherapy, subjective symptoms were relieved and oral intake was increased. Computed tomography showed that the volume of gastric wall, the size of paraaortic lymph node, and the amount of pleural effusion and ascites were decreased. Grade 1 alopecia, vasculitis and grade 2 neutropenia were observed as adverse reactions to the treatment. S-1/PTX combination therapy after endoscopic intervention was effective in this case of advanced gastric cancer with pyloric stenosis and obstructive jaundice.

Endoscopic therapy of benign pyloric stenosis and gastric outlet obstruction.

PURPOSE OF REVIEW: To examine the short and long-term success rates of balloon dilation of pyloric stenosis. RECENT FINDINGS: Several large studies have demonstrated high rates of success for the relief of symptoms from pyloric stenosis using through-the-scope balloons. These dilating balloons readily increase the diameter of the stenotic pylorus on average from 6 to 16 mm. Patients who require more than two dilations are at high risk of endoscopic failure and the need for surgical intervention. Rapid re-stenosis rates are observed in patients with malignant pyloric obstruction. Since many patients with benign pyloric stenosis have underlying ulcer disease, helicobacter infection is a relatively common finding. Eradication of this infection at the time of balloon dilation will ensure higher long-term success rates. SUMMARY: In summary, benign pyloric stenosis can be readily treated with endoscopic balloon dilation and should be the first-line therapy.

[Peptic pyloroduodenal strictures treated by endoscopic balloon dilation and eradication of helicobacter pylori. Results of a prospective study]. / Traitement de la stenose ulcereuse pyloro-bulbaire par dilatation endoscopique et eradication de Helicobacter pylori. Resultats d'une etude prospective de 16 cas.

Endoscopic dilatation of pyloro-duodenal peptic stenosis is a safe and efficient procedure that constitutes an alternative choice to surgical management. Our aims is to evaluate efficiency of endoscopic balloon dilatation associated with Helicobacter pylori eradication. During a period of 3 years (January 1999-December 2001). 16 patients were included in this study. Successful endoscopic dilatation was obtained in 15 of them (93, 75%). No severe complications (perforations) happened. All patients were infected by Helicobacter pylori. The mean follow-up was 13 months. Endoscopic balloon dilatation associated with Helicobacter pylori eradication is a safe and efficient treatment of pyloro-duodenal peptic stenosis.

Is Helicobacter pylori a cause of infantile hypertrophic pyloric stenosis?

My hypothesis is that infantile hypertrophic pyloric stenosis (IHPS) is caused in some cases by Helicobacter pylori (HP) a bacterium commonly found in the human stomach. IHPS is an idiopathic condition of infancy. It occurs at about 5 weeks of age in 3 per 1000 newborns. Children with IHPS have structurally normal pylori at birth and do not resemble children with congenital anomalies. Some nonspecific evidence (temporal distribution, seasonality, familial clustering, leukocytic infiltrates, and increased risk with bottle feeding) are compatible with an infectious etiology. Some other epidemiologic features of IHPS, such as its strong male predominance, its racial and social class variation, and a possible drop in its incidence, are also features of HP infection. Clinical features of IHPS, such as vomiting, hematemesis, and esophagitis, are also consistent with HP. Finally, children with IHPS appear to be more likely to develop chronic conditions, such as peptic ulcers, now known to be caused by HP.

[Lymph node and cutaneous tuberculosis revealed by a pyloroduodenal stenosis: a case report]. / Tuberculose ganglio-cutanée révélée par une sténose pyloro-duodénale: à propos d'un cas.

Lymphadenitis is the most frequent form of extrapulmonary tuberculosis. In immunocompetent patients, its clinical presentation is usually superficial, less frequently intra-abdominal located, and exceptionnally symptomatic. We report a case of scrofuloderma characterized by the lymph nodes extent of spread which led to a pyloro-duodenal stenosis. An 18 years old immunocompetend man is admitted in the internal medicine department, presenting a pyloroduodenal stenosis syndrome, fever, weight loss, and ulcerated axillary and cervical lymph nodes. The upper gastrointestinal endoscopy and ultrasound examination reveal the extrinsic duodenal compression by large numerous lymph node. A biopsy confirms the tuberculosis disease for which no other localisation was detected. Despite of the diagnostic and therapeutic delay, which explains the expanse and depth of the lesions, the antituberculosis therapy was effective on the digestive symptom and cleared all the cutaneous manifestations.

Antimicrobial treatment for peptic stenosis: a prospective study.

OBJECTIVE: Peptic stenosis, a complication of peptic ulcer disease, is treated by endoscopic balloon dilation or surgery. However, recent reports showed that Helicobacter pylori eradication may resolve peptic stenosis. Thus, we carried out a prospective study on a cohort of patients with peptic stenosis and H. pylori infection to evaluate the efficacy of anti- H. pylori therapy in the treatment of peptic stenosis. DESIGN/METHODS: From May 1995 to May 1998 we studied 22 consecutive patients with benign peptic stenosis (16 with duodenal stenosis and six with pyloric stenosis) and H. pylori infection. Searches for H. pylori were made at first diagnosis of peptic stenosis and at every endoscopic control. All patients were treated with an anti- H. pylori treatment (13 with omeprazole/clarithromycin/ metronidazole and nine with omeprazole/amoxycillin/ clarithromycin), followed by 8 weeks' therapy with a proton-pump inhibitor. Endoscopic controls were performed after the end of H. pylori-eradication therapy, at 2 and 6 months, and then every 6 months. RESULTS: H. pylori eradication was achieved in all patients. Peptic stenosis disappeared completely in 20/22 cases (17/20 after 2 months and 3/20 after 6 months), and in all these patients the symptoms disappeared within 2 months. At the median follow-up of 12.4 months (range 2-24), the patients remained asymptomatic, without recurrence of the stenosis, and needed no medication. In one patient the stenosis disappeared partially and symptoms improved, and it was successfully treated with cisapride. In one patient the stenosis did not disappear despite H. pylori eradication and continuous proton-pump inhibitor treatment. The patient was treated with a liquid diet due to old age, but he died 4 months after H. pylori eradication due to stroke. CONCLUSIONS: H. pylori eradication is a safe and effective therapy for peptic stenosis. Endoscopic balloon dilation or surgery should be used only after failure of this conservative treatment.